EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Liraglutide, a GLP-1 Receptor Agonist, Mitigates LPS-Induced Osteoclastogenesis and Bone Loss by Downregulating Macrophage TNF-α Expression

Kou Murakami, Hideki Kitaura iD, Fumitoshi Ohori, Aseel Marahleh iD, Angyi Lin iD, Ziqiu Fan iD, Kohei Narita, Tomoko Ishiyama, Jin Hu iD, Huidan Zheng, Hiroyasu Kanetaka

International Journal of Molecular Sciences · 22.06.2026 · 27 (12) · 5624

DOI: 10.3390/ijms27125624 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.06.2026. Verfasst von Kou Murakami und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Orthodontics and Dentofacial Orthopedics, Tohoku University Graduate School of Dentistry, 4-1 Seiryo-Machi, Aoba-ku, Sendai 980-8575, Jap…. Hauptthemen laut MEDLINE: Liraglutide, Tumor Necrosis Factor-alpha, Bone Resorption, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, restores hyperglycemic conditions in patients with type 2 diabetes and has recently shown promising anti-inflammatory properties. In this study, we explored its potential to suppress osteoclast formation and bone loss triggered by lipopolysaccharide (LPS), an inflammatory agent. In animal models, the co-administration of liraglutide with LPS on the calvaria regions in mice markedly reduced osteoclast numbers and bone resorption areas relative to treatment with LPS alone. Furthermore, the expression levels of receptor activators of the NF-κB ligand (RANKL) and tumor necrosis factor (TNF)-α mRNA were notably lower in the group receiving liraglutide and LPS compared to treatment with LPS alone. Moreover, in vitro tests revealed that liraglutide has no direct inhibitory effect on RANKL-induced osteoclastogenesis and TNF-α-induced osteoclastogenesis. In addition, liraglutide had no direct inhibitory effect on LPS-stimulated RANKL expression in osteoblasts. Moreover, liraglutide effectively suppressed TNF-α mRNA expression in macrophages stimulated by LPS. These findings suggest that liraglutide prevents inflammatory bone destruction not by targeting osteoclast formation directly but by inhibiting the production of TNF-α within macrophages.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiraglutideTumor Necrosis Factor-alphaBone ResorptionGlucagon-Like Peptide-1 Receptor AgonistsMacrophagesOsteogenesisAnimalsLipopolysaccharidesMiceOsteoclastsMaleRANK LigandDown-RegulationOsteoblastsMice, Inbred C57BL

Stichwörter der Autor:innen

bonebone resorptiondiabetesliraglutideosteoclast

Substanzen

LiraglutideTumor Necrosis Factor-alphaLipopolysaccharidesGlucagon-Like Peptide-1 Receptor AgonistsRANK Ligand

Autor:innen und Institutionen

  • Division of Orthodontics and Dentofacial Orthopedics, Tohoku University Graduate School of Dentistry, 4-1 Seiryo-Machi, Aoba-ku, Sendai 980-8575, Japan.
  • Creative Interdisciplinary Research Division, Frontier Research Institute for Interdisciplinary Sciences, Tohoku University, 6-3 Aramaki aza Aoba Aoba-ku, Sendai 980-8578, Japan.
  • Division of Advanced Dental Science and Technology, Graduate School of Biomedical Engineering, Tohoku University, 6-6-12, Aramaki Aza Aoba Aoba-ku, Sendai 980-8579, Japan.
  • Division of Interdisciplinary Co-Creation (ICC-Division), Liaison Center for Innovative Dentistry, Tohoku University Graduate School of Dentistry, 4-1 Seiryo-Machi, Aoba-ku, Sendai 980-8575, Japan.

ORCID-Profile: Hideki Kitaura, Aseel Marahleh, Angyi Lin, Ziqiu Fan, Jin Hu

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Murakami, K., Kitaura, H., Ohori, F., Marahleh, A., Lin, A., Fan, Z., Narita, K., Ishiyama, T., Hu, J., Zheng, H., & Kanetaka, H. (2026). Liraglutide, a GLP-1 Receptor Agonist, Mitigates LPS-Induced Osteoclastogenesis and Bone Loss by Downregulating Macrophage TNF-α Expression. International Journal of Molecular Sciences, 27(12), 5624. https://doi.org/10.3390/ijms27125624

Vancouver

Murakami K, Kitaura H, Ohori F, Marahleh A, Lin A, Fan Z, et al. Liraglutide, a GLP-1 Receptor Agonist, Mitigates LPS-Induced Osteoclastogenesis and Bone Loss by Downregulating Macrophage TNF-α Expression. International Journal of Molecular Sciences. 2026;27(12):5624. doi:10.3390/ijms27125624

BibTeX
@article{Murakami2026,
  author = {Murakami, Kou and Kitaura, Hideki and Ohori, Fumitoshi and Marahleh, Aseel and Lin, Angyi and Fan, Ziqiu and Narita, Kohei and Ishiyama, Tomoko and Hu, Jin and Zheng, Huidan and Kanetaka, Hiroyasu},
  title = {Liraglutide, a GLP-1 Receptor Agonist, Mitigates LPS-Induced Osteoclastogenesis and Bone Loss by Downregulating Macrophage TNF-α Expression},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {12},
  pages = {5624},
  doi = {10.3390/ijms27125624}
}
Kostenlos starten →